IKT vs PRTA vs IONS vs BIIB vs REGN

For growth investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger pick with 33. 9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 7x versus Biogen Inc. at 22. 6x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 13. 2x.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +94. 6%, compared to -95. 3% for Inhibikase Therapeutics, Inc. (IKT). Over 10 years, the gap is even starker: IONS returned +241. 3% versus IKT's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 40β versus Inhibikase Therapeutics, Inc. 's 1. 92β — meaning IKT is approximately 373% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ionis Pharmaceuticals, Inc.

(IONS) is pulling ahead at 33. 9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Inhibikase Therapeutics, Inc. grew EPS 57. 8% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, IONS leads at 17. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Regeneron Pharmaceuticals, Inc.

(REGN) trades at 13. 2x forward P/E versus 176. 7x for Prothena Corporation plc — 163. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IKT: 199. 4% to $5. 00.

In this comparison, REGN (0.

6% yield) pays a dividend. IKT, PRTA, IONS, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), 0. 6% yield). Inhibikase Therapeutics, Inc. (IKT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +68. 2%, IKT: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IKT is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock; BIIB is a mid-cap quality compounder stock; REGN is a mid-cap deep-value stock. REGN pays a dividend while IKT, PRTA, IONS, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.